Eculizumab in Transplant-Associated Thrombotic Microangiopathy

Prajwal Dhakal, Smith Giri, Ranjan Pathak, Vijaya R Bhatt

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Introduction: Transplant-associated thrombotic microangiopathy (TA-TMA) is a rare entity with no standard of care and high mortality, despite the use of plasma exchange. Methods: Using specific search terms, all cases having TA-TMA treated with eculizumab and indexed in MEDLINE (English language only) by November 2014 were reviewed. Results: A total of 26 cases, 53% men, had a median age of 33 years (range 2-61). Transplant-associated thrombotic microangiopathy occurred after stem-cell transplant (35%) or solid-organ transplant (65%), frequently associated with the use of cyclosporine or tacrolimus (96%). A disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS 13) level was always >10%. After TA-TMA diagnosis, the following drug adjustments were made: discontinuation of cyclosporine or tacrolimus in 45%, dose reduction in another 27%, continuation of the drugs in 23%, and switch from cyclosporine to tacrolimus in remaining 5%. Plasma exchange was performed in 1/443%. The median interval between transplant and initiation of eculizumab was 63 days (range 11-512). A median of 5.5 doses (range 2-21) of eculizumab was utilized with 92% response occurring after a median of 2 doses (range 1-18). At a median follow-up of 52 weeks (range 3-113), the survivors (92%) were doing well. Conclusion: Within the limits of this retrospective analysis, our study demonstrates that eculizumab use may result in high response rate and 1-year survival in patients with TA-TMA refractory to discontinuation of calcineurin inhibitor and plasma exchange.

Original languageEnglish (US)
Pages (from-to)175-180
Number of pages6
JournalClinical and Applied Thrombosis/Hemostasis
Volume23
Issue number2
DOIs
StatePublished - Mar 1 2017

Fingerprint

Thrombotic Microangiopathies
Transplants
Plasma Exchange
Tacrolimus
Cyclosporine
Thrombospondin 1
Disintegrins
eculizumab
Metalloproteases
Standard of Care
MEDLINE
Pharmaceutical Preparations
Survivors
Language
Stem Cells
Survival
Mortality

Keywords

  • calcineurin inhibitors
  • eculizumab
  • solid-organ transplant
  • stem cell transplant
  • thrombotic microangiopathy

ASJC Scopus subject areas

  • Hematology

Cite this

Eculizumab in Transplant-Associated Thrombotic Microangiopathy. / Dhakal, Prajwal; Giri, Smith; Pathak, Ranjan; Bhatt, Vijaya R.

In: Clinical and Applied Thrombosis/Hemostasis, Vol. 23, No. 2, 01.03.2017, p. 175-180.

Research output: Contribution to journalArticle

Dhakal, Prajwal ; Giri, Smith ; Pathak, Ranjan ; Bhatt, Vijaya R. / Eculizumab in Transplant-Associated Thrombotic Microangiopathy. In: Clinical and Applied Thrombosis/Hemostasis. 2017 ; Vol. 23, No. 2. pp. 175-180.
@article{d5aeb6b9711c42d7b8b8ba315b78fb71,
title = "Eculizumab in Transplant-Associated Thrombotic Microangiopathy",
abstract = "Introduction: Transplant-associated thrombotic microangiopathy (TA-TMA) is a rare entity with no standard of care and high mortality, despite the use of plasma exchange. Methods: Using specific search terms, all cases having TA-TMA treated with eculizumab and indexed in MEDLINE (English language only) by November 2014 were reviewed. Results: A total of 26 cases, 53{\%} men, had a median age of 33 years (range 2-61). Transplant-associated thrombotic microangiopathy occurred after stem-cell transplant (35{\%}) or solid-organ transplant (65{\%}), frequently associated with the use of cyclosporine or tacrolimus (96{\%}). A disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS 13) level was always >10{\%}. After TA-TMA diagnosis, the following drug adjustments were made: discontinuation of cyclosporine or tacrolimus in 45{\%}, dose reduction in another 27{\%}, continuation of the drugs in 23{\%}, and switch from cyclosporine to tacrolimus in remaining 5{\%}. Plasma exchange was performed in 1/443{\%}. The median interval between transplant and initiation of eculizumab was 63 days (range 11-512). A median of 5.5 doses (range 2-21) of eculizumab was utilized with 92{\%} response occurring after a median of 2 doses (range 1-18). At a median follow-up of 52 weeks (range 3-113), the survivors (92{\%}) were doing well. Conclusion: Within the limits of this retrospective analysis, our study demonstrates that eculizumab use may result in high response rate and 1-year survival in patients with TA-TMA refractory to discontinuation of calcineurin inhibitor and plasma exchange.",
keywords = "calcineurin inhibitors, eculizumab, solid-organ transplant, stem cell transplant, thrombotic microangiopathy",
author = "Prajwal Dhakal and Smith Giri and Ranjan Pathak and Bhatt, {Vijaya R}",
year = "2017",
month = "3",
day = "1",
doi = "10.1177/1076029615599439",
language = "English (US)",
volume = "23",
pages = "175--180",
journal = "Clinical and Applied Thrombosis/Hemostasis",
issn = "1076-0296",
publisher = "SAGE Publications Inc.",
number = "2",

}

TY - JOUR

T1 - Eculizumab in Transplant-Associated Thrombotic Microangiopathy

AU - Dhakal, Prajwal

AU - Giri, Smith

AU - Pathak, Ranjan

AU - Bhatt, Vijaya R

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Introduction: Transplant-associated thrombotic microangiopathy (TA-TMA) is a rare entity with no standard of care and high mortality, despite the use of plasma exchange. Methods: Using specific search terms, all cases having TA-TMA treated with eculizumab and indexed in MEDLINE (English language only) by November 2014 were reviewed. Results: A total of 26 cases, 53% men, had a median age of 33 years (range 2-61). Transplant-associated thrombotic microangiopathy occurred after stem-cell transplant (35%) or solid-organ transplant (65%), frequently associated with the use of cyclosporine or tacrolimus (96%). A disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS 13) level was always >10%. After TA-TMA diagnosis, the following drug adjustments were made: discontinuation of cyclosporine or tacrolimus in 45%, dose reduction in another 27%, continuation of the drugs in 23%, and switch from cyclosporine to tacrolimus in remaining 5%. Plasma exchange was performed in 1/443%. The median interval between transplant and initiation of eculizumab was 63 days (range 11-512). A median of 5.5 doses (range 2-21) of eculizumab was utilized with 92% response occurring after a median of 2 doses (range 1-18). At a median follow-up of 52 weeks (range 3-113), the survivors (92%) were doing well. Conclusion: Within the limits of this retrospective analysis, our study demonstrates that eculizumab use may result in high response rate and 1-year survival in patients with TA-TMA refractory to discontinuation of calcineurin inhibitor and plasma exchange.

AB - Introduction: Transplant-associated thrombotic microangiopathy (TA-TMA) is a rare entity with no standard of care and high mortality, despite the use of plasma exchange. Methods: Using specific search terms, all cases having TA-TMA treated with eculizumab and indexed in MEDLINE (English language only) by November 2014 were reviewed. Results: A total of 26 cases, 53% men, had a median age of 33 years (range 2-61). Transplant-associated thrombotic microangiopathy occurred after stem-cell transplant (35%) or solid-organ transplant (65%), frequently associated with the use of cyclosporine or tacrolimus (96%). A disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS 13) level was always >10%. After TA-TMA diagnosis, the following drug adjustments were made: discontinuation of cyclosporine or tacrolimus in 45%, dose reduction in another 27%, continuation of the drugs in 23%, and switch from cyclosporine to tacrolimus in remaining 5%. Plasma exchange was performed in 1/443%. The median interval between transplant and initiation of eculizumab was 63 days (range 11-512). A median of 5.5 doses (range 2-21) of eculizumab was utilized with 92% response occurring after a median of 2 doses (range 1-18). At a median follow-up of 52 weeks (range 3-113), the survivors (92%) were doing well. Conclusion: Within the limits of this retrospective analysis, our study demonstrates that eculizumab use may result in high response rate and 1-year survival in patients with TA-TMA refractory to discontinuation of calcineurin inhibitor and plasma exchange.

KW - calcineurin inhibitors

KW - eculizumab

KW - solid-organ transplant

KW - stem cell transplant

KW - thrombotic microangiopathy

UR - http://www.scopus.com/inward/record.url?scp=85011695992&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011695992&partnerID=8YFLogxK

U2 - 10.1177/1076029615599439

DO - 10.1177/1076029615599439

M3 - Article

C2 - 26259912

AN - SCOPUS:85011695992

VL - 23

SP - 175

EP - 180

JO - Clinical and Applied Thrombosis/Hemostasis

JF - Clinical and Applied Thrombosis/Hemostasis

SN - 1076-0296

IS - 2

ER -